StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 5/30
$1.34−0.06 (-4.61%)

Close on Nov 18, 2026Market cap $1.36MP/E –Yield –

Transcode Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Transcode Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$45.13M. For fiscal 2025 it was -$27.98M. The highest annual figure on record is -$726.60K in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.98M–
FY2024Dec 31, 2024-$15.66M–
FY2023Dec 31, 2023-$19.42M–
FY2022Dec 31, 2022-$18.63M–
FY2021Dec 31, 2021-$6.15M–
FY2020Dec 31, 2020-$726.60K–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$6.79M–
Q1 FY2026Mar 31, 2026-$17.76M–
Q4 FY2025Dec 31, 2025-$16.03M–
Q3 FY2025Sep 30, 2025-$4.56M–
Q2 FY2025Jun 30, 2025-$4.22M–
Q1 FY2025Mar 31, 2025-$3.17M–
Q4 FY2024Dec 31, 2024-$5.09M–
Q3 FY2024Sep 30, 2024-$2.17M–
Q2 FY2024Jun 30, 2024-$5.11M–
Q1 FY2024Mar 31, 2024-$3.29M–
Q4 FY2023Dec 31, 2023-$4.10M–
Q3 FY2023Sep 30, 2023-$5.31M–
Q2 FY2023Jun 30, 2023-$5.12M–
Q1 FY2023Mar 31, 2023-$4.89M–
Q4 FY2022Dec 31, 2022-$5.50M–
Q3 FY2022Sep 30, 2022-$4.95M–
Q2 FY2022Jun 30, 2022-$4.71M–
Q1 FY2022Mar 31, 2022-$3.48M–
Q4 FY2021Dec 31, 2021-$2.99M–
Q3 FY2021Sep 30, 2021-$2.36M–
Q2 FY2021Jun 30, 2021-$355.53K–
Q1 FY2021Mar 31, 2021-$449.47K–
Q4 FY2020Dec 31, 2020-$379.00K–
Q3 FY2020Sep 30, 2020-$239.49K–
Q2 FY2020Jun 30, 2020-$91.61K–

More Transcode Therapeutics figures

See a number that looks wrong?